Tumour-infiltrating T-cell subpopulations in glioblastomas
Tumour-infiltrating T-cell subpopulations in glioblastomas
复制标题
DOI：
10.3109/02688697.2011.584986
复制
发表时间：
2012-02-01
影响因子：
1.1
通讯作者：
Lee, Je-Jung
中科院分区：
文献类型：
--
作者：
Kim, Young-Hee;Jung, Tae-Young;Lee, Je-Jung
本研究旨在确定胶质母细胞瘤中不同肿瘤浸润性T细胞群体的发病率和预后价值。我们还评估了常规治疗后T细胞群的差异。2003年至2009年4月，67例胶质母细胞瘤患者接受了手术。采用免疫组化法检测CD 3、CD 4、CD 8和FoxP 3，计算平均阳性细胞数和阳性细胞百分比。在八名患者中，比较了第一次和第二次手术期间获得的标本之间的平均亚群数量。年龄、性别、Karnofsky体力状态、放射治疗肿瘤学小组-递归分割分析（RTOG-RPA）类别、去除程度、治疗方式、O-6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）甲基化状态和CD 4、CD 8和FoxP 3的免疫阳性被分析为预后因素。平均有12.8 +/-1.8的CD 31 T细胞、1.5 +/-0.5的CD 41 T细胞、6.8 +/-1.3的CD 81 T细胞和0.6 +/-0.2的FoxP 3细胞。CD 3、CD 4、CD 8和FoxP 3的阳性T细胞亚群百分比分别为89.6%、22.4%、77.6%和34.3%。在8例患者中，第一次和第二次手术的亚群没有差异。中位无进展生存期为7.0个月（95% CI，5.2-8.9个月），总生存期为14.8个月（95% CI，11-18.7个月）。单变量分析显示，CD 8的无进展生存期（p = 0.02）和RTOG-RPA类别的总生存期（p = 0.003）、去除程度（p = 0.01）和MGMT启动子甲基化状态（p = 0.005）存在统计学显着差异。基于多变量分析，RTOG-RPA分类与较长的总生存期显著相关。肿瘤内免疫反应经常发生在胶质母细胞瘤中，并且即使在常规治疗后也有一致的反应。在免疫豁免的中枢神经系统中，CD 81 T细胞的无进展生存期存在统计学显著差异。
This study was designed to determine the incidence and prognostic value of various populations of tumour-infiltrating T cells in glioblastomas. We also evaluated the difference in T-cell populations after conventional treatment. Sixty-seven patients with glioblastomas underwent surgery between 2003 and April 2009. Immunohistochemical staining was performed for CD3, CD4, CD8 and FoxP3, and the average number and percentage of positive cells were calculated. In eight patients, the average number of subpopulations was compared between the specimens obtained during the first and second operations. Age, gender, Karnofsky performance status, Radiation Therapy Oncology Group-recursive partitioning analysis (RTOG-RPA) classes, extent of removal, treatment modality, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and immunopositivity for CD4, CD8 and FoxP3 were analyzed as prognostic factors. There was an average of 12.8 +/- 1.8 CD31 T cells, 1.5 +/- 0.5 CD41 T cells, 6.8 +/- 1.3 CD81 T cells and 0.6 +/- 0.2 FoxP3 cells. The percentage of positive T-cell subpopulations was 89.6%, 22.4%, 77.6% and 34.3% for CD3, CD4, CD8 and FoxP3, respectively. In eight patients, there was no difference in the subpopulations between the first and second operations. The median progression-free survival was 7.0 months (95% CI, 5.2-8.9 months) and the overall survival was 14.8 months (95% CI, 11-18.7 months). Univariate analysis showed a statistically significant difference in progression-free survival for CD8 (p = 0.02) and overall survival for RTOG-RPA classes (p = 0.003), the extent of removal (p = 0.01) and MGMT promoter methylation status (p = 0.005). Based on multivariate analysis, RTOG-RPA classes were significantly associated with longer overall survival. The intratumoural immune response occurred frequently in glioblastomas and there was a consistent response, even after conventional treatment. There was a statistically significant difference in progression-free survival for CD81 T cells in immunologically privileged central nervous system.